Following on from information provided to NICE by the company in May 2017 the appraisal of Lymphoma (Hodgkin, relapsed, refractory) - nivolumab (after ASCT) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1103 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Discontinued. Following on from information provided to NICE by the company in May 2017 the appraisal of Lymphoma (Hodgkin, relapsed, refractory) - nivolumab (after ASCT) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 16 June 2017 | Suspended. The company have advised that they will not be pursuing a licensing application for nivolumab from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme for the time being. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes. |
| 22 July 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual